Quantcast

Latest Hypolipidemic agent Stories

2008-09-03 09:00:04

By MARIA CHENG By Maria Cheng The Associated Press MUNICH, Germany Results so far from three studies of the cholesterol-lowering drug Vytorin are not enough to prove or rule out a possible link to a higher risk of cancer, so the drug should be used with caution until more is known, editors of a leading medical journal urged Tuesday. The New England Journal of Medicine published results online from one study and an analysis of partial results from two others. They also were...

2008-09-03 06:00:06

By Alex Berenson When the U.S. Food and Drug Administration approved a new type of cholesterol-lowering medicine in 2002, it did so on the basis of a handful of clinical trials covering a total of 3,900 patients. None of the patients took the medicine for more than 12 weeks, and the trials offered no evidence that the treatment had reduced heart attacks or cardiovascular disease, the goal of any cholesterol drug. The lack of evidence has not stopped doctors from heavily prescribing that...

2008-09-03 07:30:00

By Steve Sternberg The editors of a leading medical journal cautioned Tuesday that, without more data, it's impossible to rule out a link between the cholesterol-lowering drug Vytorin and cancer. The cancer link surfaced unexpectedly in July in three studies designed to show whether the drug prevents deaths from heart attacks and strokes. Researchers found evidence that patients who took Vytorin appear to have at least a 40% greater risk of dying from cancer than those who took a placebo. A...

2008-09-03 00:00:24

An editorial in the New England Journal of Medicine says more study is needed of the cholesterol-lowering drugs Zetia and Vytorin. Researchers reported last month that patients in three clinical trials had a 40 percent higher chance of dying of cancer if they took Vytorin instead of a placebo, the New York Times reported Tuesday. Vytorin is a combination drug containing ezetimibe, the generic name for Zetia. Drug makers Merck and Schering-Plough say ezetimibe showed no cancer risk in...

2008-07-25 06:00:18

By Steve Sternberg A study that unexpectedly linked the heart drug Vytorin to excess cancer deaths has provoked controversy among heart specialists worried that the drug's risks may outweigh its benefits. The study, called SEAS, was designed to test whether Vytorin could prevent severe, age-related heart valve problems by sharply reducing cholesterol. But lead investigator Terje Pedersen of Ulleval University Hospital in Oslo reported Monday that the study turned up a "disturbing" link...

2008-07-24 15:00:15

By ALICIA CHANG, THE ASSOCIATED PRESS Scientists may have found a way to test for and possibly avoid the most serious side effect of cholesterol-lowering statin drugs, one of the top-selling medicines in the world. In rare cases, statins can cause muscle pain and weakness. Researchers have identified a genetic variation that seems to predict more than half of these cases. People on statins who have the variant were about five to 17 times more likely to develop muscle problems, a serious...

2008-07-23 15:00:31

By JANJARVIS FORT WORTH, Texas - Beverly Morgan of Arlington, Texas, was 16 when she started taking the popular cholesterol-lowering drug Vytorin. But she eventually abandoned the medication. "I would rather control my cholesterol with exercise and diet simply because when you do put drugs in your body, you're going to have side effects," said Morgan, 19, a student at Mountain View Community College in Dallas. "I try to take as little medications as possible." While many people share...

2008-07-22 00:00:16

By Jan Jarvis FORT WORTH, Texas - Beverly Morgan of Arlington, Texas, was 16 when she started taking the popular cholesterol-lowering drug Vytorin. However, she eventually abandoned the medication. "I would rather control my cholesterol with exercise and diet, simply because when you do put drugs in your body, you're going to have side effects," said Morgan, 19, a student at Mountain View Community College in Dallas. "I try to take as little medications as possible." While many people...

2008-07-17 15:01:02

The American Academy of Pediatrics (AAP) released new guidelines on July 7, 2008, recommending that some children as young as 8 years old be given cholesterol-fighting drugs to ward off future heart problems. It is the strongest guidance ever given by the AAP. Madeira Therapeutics, a pediatric drug-development company, currently has a statin, a cholesterol-lowering product, in the development pipeline focused on this need. The new guidelines set by the AAP are based on evidence showing that...

2008-07-14 09:00:14

My daughter Kaitlyn is 8 years old. According to the American Academy of Pediatrics, she's ready for cholesterol-lowering drugs. Yes, you read that right. In a move that has left many parents incredulous, the nation's pediatricians recently issued new guidelines calling for cholesterol screening of children as young as 2 _ and cholesterol drugs for kids as young as 8. Without intervention, the doctors say, today's overweight youngsters are doomed to become tomorrow's heart patients. Do we...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related